rallybio is a privately-held early-stage biotechnology company incorporated in january 2018. our ambition is to create a world-leading biotechnology organization that transforms the lives of patients with devastating disease, built around people with an outstanding track record in pharmaceutical research and development. we will work on highly-promising drug candidates that have strong biological rationales and that can be addressed using the well-validated therapeutic modalities of small molecules, engineered proteins, and antibodies. rallybio’s founders are seasoned leaders from the biopharma industry with a wide breadth of research, development, and financial experience. the company is based in farmington, ct, at the university of connecticut’s technology incubation program. we are assembling a small team of people with an outstanding track record in pharmaceutical research and development to search for and evaluate assets using a series of robust clinical and commercial filters tha
Company profile
Ticker
RLYB
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Rallybio Holdings, LLC
SEC CIK
Corporate docs
Subsidiaries
Rallybio, LLC • Rallybio IPA, LLC • Rallybio IPB, LLC • IPC Research, LLC • Rallybio IPE, LLC • Rallybio IPF, LLC ...
IRS number
823919910
RLYB stock data
Latest filings (excl ownership)
D
$6.60 mm in equity, sold $6.60 mm, 1 investor
22 Apr 24
DEF 14A
Definitive proxy
11 Apr 24
8-K
Entry into a Material Definitive Agreement
10 Apr 24
S-8
Registration of securities for employees
13 Mar 24
10-K
2023 FY
Annual report
12 Mar 24
8-K
Rallybio Reports Fourth Quarter and Full Year 2023 Financial Results
12 Mar 24
8-K
Rallybio Announces Portfolio Prioritization and Provides Corporate Update
6 Feb 24
8-K
Regulation FD Disclosure
20 Dec 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Rallybio Reports Third Quarter 2023 Financial Results and Provides Business Updates
9 Nov 23
Latest ownership filings
4
Stephen Uden
16 Feb 24
4
MARTIN MACKAY
16 Feb 24
4
Jonathan I Lieber
16 Feb 24
4
Steven Ryder
16 Feb 24
SC 13G/A
VIKING GLOBAL INVESTORS LP
14 Feb 24
SC 13D/A
Pivotal bioVenture Partners Fund I, L.P.
12 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
4
KUSH PARMAR
4 Jan 24
4
RONALD HUNT
4 Jan 24
SC 13G/A
Novo Holdings A/S
2 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 19.16 mm | 19.16 mm | 19.16 mm | 19.16 mm | 19.16 mm | 19.16 mm |
Cash burn (monthly) | 4.47 mm | 2.71 mm | 6.45 mm | 6.24 mm | 5.49 mm | 5.32 mm |
Cash used (since last report) | 31.07 mm | 18.87 mm | 44.89 mm | 43.41 mm | 38.18 mm | 37.02 mm |
Cash remaining | -11.91 mm | 291.81 k | -25.73 mm | -24.26 mm | -19.03 mm | -17.87 mm |
Runway (months of cash) | -2.7 | 0.1 | -4.0 | -3.9 | -3.5 | -3.4 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 62 |
Opened positions | 5 |
Closed positions | 6 |
Increased positions | 13 |
Reduced positions | 14 |
13F shares | Current |
---|---|
Total value | 105.15 bn |
Total shares | 40.16 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Viking Global Investors | 4.19 mm | $14.14 bn |
5AM Venture Management | 3.63 mm | $12.24 bn |
New Leaf Venture Partners, L.L.C. | 3.30 mm | $11.13 bn |
FMR | 3.25 mm | $10.94 bn |
TPG GP A | 3.03 mm | $10.21 bn |
5AM Ventures V | 2.48 mm | $22.96 mm |
Pivotal bioVenture Partners Investment Advisor | 2.40 mm | $8.10 bn |
Pivotal bioVenture Partners Fund I | 2.27 mm | $40.88 mm |
Novo Holdings A/S | 2.19 mm | $7.37 bn |
New Leaf Ventures III | 2.15 mm | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Feb 24 | Stephen Uden | Option Common Stock | Grant | Acquire A | No | No | 1.86 | 216,000 | 401.76 k | 216,000 |
15 Feb 24 | Mackay Martin | Option Common Stock | Grant | Acquire A | No | No | 1.86 | 216,000 | 401.76 k | 216,000 |
15 Feb 24 | Lieber Jonathan I | Option Common Stock | Grant | Acquire A | No | No | 1.86 | 120,000 | 223.20 k | 120,000 |
15 Feb 24 | Steven Ryder | Option Common Stock | Grant | Acquire A | No | No | 1.86 | 120,000 | 223.20 k | 120,000 |
2 Jan 24 | Hunt Ronald | Option Common Stock | Grant | Acquire A | No | No | 1.77 | 29,096 | 51.50 k | 29,096 |
News
JMP Securities Reiterates Market Outperform on Rallybio, Maintains $8 Price Target
19 Apr 24
Rallybio Corporation Announces FNAIT Systematic Literature Review And Meta-Analysis Presented At The Academy Of Managed Care Pharmacy 2024 Annual Meeting
17 Apr 24
12 Health Care Stocks Moving In Monday's Intraday Session
15 Apr 24
Why JPMorgan Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Friday's Mid-Day Session
12 Apr 24
12 Health Care Stocks Moving In Friday's Intraday Session
12 Apr 24
Press releases
FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meeting
17 Apr 24
Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
10 Apr 24
Rallybio Announces FNAIT Systematic Literature Review to be Presented at the AMCP 2024 Annual Meeting
1 Apr 24